Had pertinent data relating to chemical inactivation of CHO cells been available at the start-up of our facility, it would
have been possible to move quickly and directly to an annual verification of the chosen methods. This paper should supply
to other groups valuable in-formation that may be used in justifying the selection and use of similar inactivation procedures
in their own facilities.
Mary Heenan, senior scientist, Process Development, Development & Technical Services, The Wyeth BioPharma Campus at Grange Castle, Wyeth Medica Ireland, Grange Castle International Business Park, Clondalkin Dublin 22, Ireland, 01.4696814, Fax: 01.4696896, firstname.lastname@example.org
1. Fink R, Moran E. Biosafety for large-scale containment level 1 operations using recombinant DNA technology: No emerging
hazards. Applied Biosafety. 2005; 10:30-39.
2. Ebling MJ, Miller S. Validation of a batch type biological waste treatment system. Pharmaceutical Engineering. 1991;11:42-48.
3. Carlson CJ. Biowaste Systems. Pharmaceutical Engineering. 2001;21:70-82.
4. Gregoriades N, Luzardo M, Lucquet B, Ryll T. Heat inactivation of mammalian cell cultures for biowaste kill system design.
Biotechnol. Prog. 2003;19:14-20.
5. Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001.